Themes Involving Clinical Trials at the 2024 DIA Global Annual Meeting

Pierce: I think it tied perfectly with the FDA releasing a guidance right after GAM (Global Annual Meeting) on the DE&I initiatives, and really diversity, equity, and inclusion in clinical trials, and we saw a lot of conversation on that. I think it's a place that we heard a lot of topics and a lot of discussion in the in the hallways, really around inclusion of the patient voice, and how do we make sure that we do tap into these diverse data sets, so that we're really creating products and improving products that relate to the people that they're intended to treat? It's been a challenge, and it continues to be a challenge, and so I think the industry is looking for guidance from the regulators. The regulators are looking for feedback on how it's working, because there's a reality of what perfect might look like, but then can you actually recruit those patients and get them into the studies? I would say that is really the highlight that I'm aware of, and I think it will continue to be a topic that everyone is continuing to speak about and continuing to try to address that and really figuring out—how do we make sure that what we're creating for patients is really working in the way that it's intended? We've incorporated that patient voice into the process early on, instead of after they receive the product, and we're getting feedback after the fact.